Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELODY
2019-000114-11Phase 3Completed
- Sponsor
- MedImmune
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing nirsevimab with placebo (2 arms). Primary endpoint: Incidence of medically attended RSV lower respiratory tract infection. Started Jul 2019; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-000114-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000114-11.